CTLA4 and neoplasm: The development of immune checkpoint inhibitors has resulted in significant breakthroughs in tumor treatment, with the most often employed immune checkpoints being PD-1, TIM-3, CTLA-4, LAG-3, CEACAM1, and TIGIT [30].